Drugs / APC8020
last change Nov 2007 re-read 2 minutes ago

APC8020

Vaccine

Developed for
plasma cell myeloma
Investigated by
Mayo Clinic · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00616720 Aug 2001 → Nov 2007 plasma cell myeloma Mayo Clinic Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as APC8020 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00616720
Modality Vaccine “dendritic cell vaccine APC8020” NCT00616720
Route Intravenous “idiotype-pulsed autologous dendritic cell vaccine APC8020 IV over 30-minutes on days 2, 16, and 30” NCT00616720